Global access Medicines360 is actively expanding access to women’s health products internationally, highlighted by AVIBELA’s availability in South Africa and partnerships to increase affordable, long-acting contraception; a sales opportunity lies in partnering with regional distributors and healthcare providers in emerging markets seeking LARC solutions.

Strategic partnerships Recent collaborations with Wellcome Leap and licensing from top research institutions indicate a strong move toward co-developing and commercializing maternal health technologies; sales teams should target alliance management with research organizations and funders to co-sell and co-market upcoming tools.

Pipeline expansion Acquisitions of PeriPeach licensing and ongoing development through the 360 Innovation Hub signal a broadened product pipeline in obstetric and maternal health; identify opportunities to position Medicines360 as a preferred partner for devices and diagnostics targeting pregnancy-related complications.

Emerging-tech focus Technologies under development include blood biomarker tests and non-invasive retinal imaging for pregnancy risk prediction, offering upsell or new-customer opportunities with hospitals, maternal-fetal medicine centers, and diagnostic labs seeking innovative predictive tools.

Mission-driven positioning As a mission-driven, women’s health innovator with a clear focus on affordability and access, target public health programs, NGOs, and government health initiatives that prioritize reproductive health, maternal outcomes, and density of care in low-to-middle income regions.